Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.835
-0.005 (-0.18%)
Sep 3, 2025, 11:47 AM - Market open
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $1.99M in the quarter ending June 30, 2025, with 78.60% growth. This brings the company's revenue in the last twelve months to $8.10M, down -37.09% year-over-year. In the year 2024, Taysha Gene Therapies had annual revenue of $8.33M, down -46.07%.
Revenue (ttm)
$8.10M
Revenue Growth
-37.09%
P/S Ratio
96.79
Revenue / Employee
$110,932
Employees
73
Market Cap
773.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8.33M | -7.12M | -46.07% |
Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
Dec 31, 2022 | 2.50M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TSHA News
- 21 days ago - Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 - GlobeNewsWire
- 4 weeks ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program - GlobeNewsWire
- 3 months ago - Why Is Taysha Gene Therapies Stock Trading Higher On Thursday? - Benzinga
- 3 months ago - Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 3 months ago - Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire